Idarubicin Overcomes MDR1 Induced Chemoresistance With Higher Induction Remission Rate and Quality Than Daunorubicin in Acute Myeloid Leukemia Patients
Clinical trial NCT01889407 · UNKNOWN
Trial details
- NCT number
- NCT01889407
- Sponsor
- Nanfang Hospital, Southern Medical University
- Status
- UNKNOWN
- Study type
- OBSERVATIONAL
- Start date
- 2013-08-01
- Primary completion
- 2016-07-01
- Enrollment
- 94
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.